Ultragenyx: Undervalued Ahead Of Two FDA Decisions

Ultragenyx is rated a soft Buy at $26.75, implying a probability-weighted fair value of about $32/share versus the current ~$27. The call hinges on two near-term FDA catalysts: DTX401 decision on Aug 23 and UX111 decision on Sept 19. Using 80% approval odds for DTX401 and 65% for UX111, the expected value suggests roughly 18% upside, driven by DTX401’s cleaner regulatory case but UX111’s credible approval path.

Analysis

This is a classic two-step binary setup where the stock can rerate materially even if the first decision is only partially derisked. The market is likely not fully pricing the compounding effect of a clean initial readout: approval on the first asset should lower the perceived odds of a regulatory surprise on the second by signaling that the company’s package quality and CMC execution are good enough to clear FDA scrutiny. That creates upside that is larger than a simple probability-weighted average because the second event becomes less “independent” once the first catalyst is resolved.

The risk is that the current setup looks cleaner than it is: gene-therapy names often trade on label quality, not just approval status, so a narrow indication, post-marketing burden, or manufacturing language can mute the rerate. If the first decision disappoints, the stock likely de-rates quickly and the second catalyst stops functioning as a second leg of upside; the market will treat it as a financing and execution issue, not just a regulatory miss. In that case, downside can extend beyond the event because investors will question the platform’s optionality and dilution path.

The better contrarian read is that the upside may be more than consensus expects, but the trade is timing-sensitive and should be sized for event volatility rather than steady fundamental drift. Over the next 1-3 months, the key driver is whether the first approval comes with a commercially useful label and whether management can frame the second asset as a follow-on rather than a separate risk. Over 6-18 months, successful approvals would shift RARE from a single-asset story to a platform valuation, which is where the biggest multiple expansion sits.

Key Decisions for Investors

• Long RARE into the first FDA decision only if the stock is not already pricing a near-perfect outcome; prefer a defined-risk upside structure such as a Sep/Oct call spread to capture the two-catalyst path while capping downside to premium paid.
• If event implied volatility is elevated, avoid outright long stock ahead of Aug. 23 and instead use a RARE/XBI long-short pair to isolate company-specific regulatory alpha from biotech beta.
• Take partial profits on a gap move through the probability-weighted fair value after the first approval; the second catalyst can still add value, but post-event IV crush makes chasing the move unattractive.
• Set a hard stop on thesis failure: any CRL, significant label restriction, or CMC/manufacturing deficiency should invalidate the bullish setup and justify exiting immediately rather than waiting for the later decision.